Joanna Shields, BenevolentAI CEO

AI tools don't equal guar­an­teed drug suc­cess as Benev­o­len­tAI flops der­mati­tis test

It’s a no for BEN.

BEN-2293, a top­i­cal out of Lon­don-based Benev­o­len­tAI, has failed sec­ondary ef­fi­ca­cy mea­sures in a Phase IIa study in atopic der­mati­tis. The in­ves­ti­ga­tion­al drug, one of an ear­ly gen­er­a­tion drummed up by the buzzy AI tools in biotech, works by in­hibit­ing mul­ti­ple tropomyosin-re­lat­ed ki­nas­es, which are known best in the can­cer land­scape with Bay­er’s Vi­t­rakvi and Roche’s Ro­z­lytrek.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA